NVCR
NovoCureFNasdaq / Health Care Equipment & Services
Last Price
At close
2026-07-17
Current thesis
The constructive case is that Novocure now has multiple concrete proof points rather than a pure platform story: Japan reimbursement approval for Optune Lua opens a new covered market for NSCLC [#PR-2026-03-02], PANOVA-4 reported statistically significant disease-control improvement in metastatic pancreatic cancer [#PR-2026-03-26], and management's 2026 guide implies incremental contribution from newer indications and products [#PR-2026-02-26-FY]. With the stock still near $12.67 versus a packet median target near $25.93, the setup can work if upcoming milestones convert into visible patient and revenue traction.
Posture
Defensive
Lead driver
Sentiment
What changed
2 setup hits (3d) with net bullish as of 2026-07-13.
What can break
April 30, 2026 earnings could fail to show convincing early revenue contribution from Optune Pax and Optune Lua.
Momentum
35
Value
37
Sentiment
47
Setup hits (3d)
2 · Net Bullish
AI TargetsBase $14.50 · Bull $19.00 · Bear $8.50
Earnings
2026-07-23 · BMO
Data freshness
Prices
As of 2026-07-17
Fundamentals
As of 2026-07-13 • Vendor: Data Vendor v1
Scores
As of 2026-07-17 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-21 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-17
Investment thesis
As of 2026-07-17
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Bullish
Target $24.88
Why
Momentum35 · Δ7d -44.5
Value37 · Δ7d +0.1
Sentiment47 · Δ7d +0.2
So what
Weak posture (Net Bullish). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
35
26% active weight
Current posture
7d trendSoftening
Δ7d
-44.5
Δ21d
-22.2
Value
37
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.1
Sentiment
47
34% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
-8.4
Why this grade
Composite grade F. Momentum 34.5 / Value 36.5 / Sentiment 47.5
Fundamentals (TTM)As of 2026-07-13
Fundamentals (TTM)
As of 2026-07-13
Market Cap
$1.86B
Beta
0.72
Shares Out
115.82M
P/E (TTM) · Derived
-13.2
P/S (TTM)
2.40
P/FCF (TTM) · Derived
-37.74
Rev YoY
+12.3%
EPS YoY
+100.3%
Gross Margin
+75.2%
Op Margin
-27.3%
Net Debt
-$209.16M
Current Ratio
2.90
As of 2026-07-17 • Updated nightlySource: Internal modelMethodology